AU530999B2 - Substituted amino triazines and their use in treatment of cns disorders - Google Patents

Substituted amino triazines and their use in treatment of cns disorders

Info

Publication number
AU530999B2
AU530999B2 AU58906/80A AU5890680A AU530999B2 AU 530999 B2 AU530999 B2 AU 530999B2 AU 58906/80 A AU58906/80 A AU 58906/80A AU 5890680 A AU5890680 A AU 5890680A AU 530999 B2 AU530999 B2 AU 530999B2
Authority
AU
Australia
Prior art keywords
hydrogen
formula
compound
iii
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU58906/80A
Other languages
English (en)
Other versions
AU5890680A (en
Inventor
Martin George Baxter
Albert Reginald Elphick
Alistair Ainslie Miller
David Alan Sawyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10505597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU530999(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of AU5890680A publication Critical patent/AU5890680A/en
Application granted granted Critical
Publication of AU530999B2 publication Critical patent/AU530999B2/en
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/15—Preparation of carboxylic acids or their salts, halides or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU58906/80A 1979-06-01 1980-05-30 Substituted amino triazines and their use in treatment of cns disorders Expired AU530999B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB7919257 1979-06-01
GB7919257 1979-06-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU14051/83A Division AU566870B2 (en) 1979-06-01 1983-04-28 Aminoguanidine derivative of substituted benzoyl cyanide

Publications (2)

Publication Number Publication Date
AU5890680A AU5890680A (en) 1980-12-04
AU530999B2 true AU530999B2 (en) 1983-08-04

Family

ID=10505597

Family Applications (2)

Application Number Title Priority Date Filing Date
AU58906/80A Expired AU530999B2 (en) 1979-06-01 1980-05-30 Substituted amino triazines and their use in treatment of cns disorders
AU14051/83A Expired AU566870B2 (en) 1979-06-01 1983-04-28 Aminoguanidine derivative of substituted benzoyl cyanide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU14051/83A Expired AU566870B2 (en) 1979-06-01 1983-04-28 Aminoguanidine derivative of substituted benzoyl cyanide

Country Status (30)

Country Link
US (2) US4486354A (enExample)
EP (2) EP0059987B1 (enExample)
JP (2) JPS5625169A (enExample)
AR (1) AR227521A1 (enExample)
AT (1) AT370097B (enExample)
AU (2) AU530999B2 (enExample)
BG (1) BG60427B2 (enExample)
CA (1) CA1112643A (enExample)
CS (1) CS234018B2 (enExample)
CZ (1) CZ384891A3 (enExample)
DD (1) DD151309A5 (enExample)
DK (1) DK153787C (enExample)
ES (1) ES491998A0 (enExample)
FI (1) FI67844C (enExample)
GE (1) GEP19960470B (enExample)
GR (1) GR68380B (enExample)
HU (1) HU182086B (enExample)
IE (1) IE49823B1 (enExample)
IL (1) IL60201A (enExample)
IT (1) IT1147087B (enExample)
MX (1) MX9202962A (enExample)
MY (1) MY8500062A (enExample)
NL (1) NL950007I2 (enExample)
NZ (1) NZ193890A (enExample)
PL (1) PL124029B1 (enExample)
SU (1) SU1055331A3 (enExample)
UA (1) UA5576A1 (enExample)
YU (1) YU145680A (enExample)
ZA (1) ZA803250B (enExample)
ZW (1) ZW12980A1 (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311701A (en) * 1979-08-16 1982-01-19 Barbara Roth Treatment of convulsions with triazines
GB8328757D0 (en) * 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
DE3600891A1 (de) * 1986-01-15 1987-07-16 Bayer Ag 1,8-verbrueckte 4-chinolon-3-carbonsaeuren und diese enthaltende arzneimittel
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4972496A (en) * 1986-07-25 1990-11-20 Grid Systems Corporation Handwritten keyboardless entry computer system
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
UA37214C2 (uk) * 1991-01-30 2001-05-15 Дзе Веллкам Фаундейшн Лімітед Таблетки, що диспергуються у воді, та спосіб їх виготовлення
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
CA2137782A1 (en) * 1992-06-12 1993-12-23 Meire Nakamura-Craig Therapeutic triazine compounds and use
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
FI972719L (fi) * 1994-12-30 1997-08-27 Wellcome Found Menetelmä lamotrigiinin valmistamiseksi
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6202491B1 (en) 1997-07-22 2001-03-20 Skf Condition Monitoring, Inc. Digital vibration coupling stud
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
AU1292400A (en) * 1998-12-14 2000-07-03 Sharad Kumar Vyas An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
IN183150B (enExample) * 1998-12-14 1999-09-25 Torrent Pharmaceuticals Ltd
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
AU4334900A (en) * 1999-04-09 2000-11-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
GB9907965D0 (en) 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
US6639072B1 (en) 2000-01-03 2003-10-28 Rpg Life Sciences Limited Process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
IL134730A (en) * 2000-02-25 2003-10-31 Chemagis Ltd Process for preparing substituted benzoyl cyanide amidinohydrazones
KR20030059290A (ko) 2000-11-30 2003-07-07 화이자 프로덕츠 인코포레이티드 Ｇａｂａ 작용제 및 소르비톨 데하이드로게나제 억제제의혼합물
AP2001002359A0 (en) 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
CA2439468A1 (en) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
CN1274306C (zh) 2001-09-03 2006-09-13 纽朗制药有限公司 包含加巴喷丁或其类似物和α－氨基酰胺的药物组合物及其止痛应用
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2003090693A2 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
US7521553B2 (en) * 2003-03-17 2009-04-21 Hetero Drugs Limited Crystalline forms of lamotrigine
WO2004085426A1 (en) 2003-03-27 2004-10-07 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
BRPI0507190A (pt) * 2004-01-29 2007-06-26 Pfizer Prod Inc combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
RS51411B (sr) * 2004-09-10 2011-02-28 Newron Pharmaceuticals S.P.A. Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
ES2375213T3 (es) * 2005-09-23 2012-02-27 Janssen Pharmaceutica Nv Moduladores de cannabinoides de hexadhidro-cicloheptapirazol.
UA93389C2 (en) * 2005-09-23 2011-02-10 Янссен Фармацевтика H.B. Hexahydro cyclooctyl pyrazole cannabinoid modulators
BRPI0616263A2 (pt) 2005-09-23 2011-06-14 Janssen Pharmaceutica Nv moduladores canabinàides do tipo tetrahidro-ciclopentil pirazol
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
EP1979593B1 (en) * 2006-02-03 2017-12-06 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
WO2007095513A1 (en) * 2006-02-14 2007-08-23 Janssen Pharmaceutica, Nv Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
WO2007122638A2 (en) * 2006-04-26 2007-11-01 Ratnamani Bio-Chemicals & Pharmaceuticals Pvt. Ltd. An improved process for preparation of lamotrigine intermediates
US20090312544A1 (en) * 2006-05-31 2009-12-17 Calaire Chimie Sas Method for preparing lamortrigine and its intermediate 2,3-dichlorobenzoyl chloride
GB0613836D0 (en) * 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
US20120142919A1 (en) 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
CA2659290A1 (en) * 2006-08-14 2008-02-21 Jean-Paul Roduit A process for the preparation of lamotrigine
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076010A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
WO2009061513A1 (en) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Crystalline forms of lamotrigine
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2010132691A1 (en) 2009-05-13 2010-11-18 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds
EP2564836A1 (en) 2009-05-20 2013-03-06 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
GB2471729A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
US20110052686A1 (en) * 2009-09-03 2011-03-03 Ranbaxy Laboratories Limited Modified release lamotrigine tablets
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013183985A1 (en) 2012-06-05 2013-12-12 Erasmus University Medical Center Rotterdam Method of treating cognitive impairment and compounds for use therein
US10189859B2 (en) 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
ES2858750T3 (es) 2015-06-12 2021-09-30 Univ Greenwich Derivados de triazina como inhibidores del interferón gamma
HRP20220463T1 (hr) 2016-12-16 2022-05-27 Idorsia Pharmaceuticals Ltd Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
GB2641294A (en) 2024-05-24 2025-11-26 Novumgen Ltd An orodispersible tablet of Lamotrigine and its process of preparation
US12605388B2 (en) * 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759014A (en) * 1952-02-26 1956-10-10 Wellcome Found Improvements in triazines and their manufacture
AT190941B (de) * 1954-09-22 1957-07-25 Chemie Linz Ag Verfahren zur Herstellung neuer Guanylhydrazone
US2952677A (en) * 1956-10-01 1960-09-13 Ici Ltd Aminoguanadine compounds
BE663481A (enExample) * 1964-05-05
DE1802364C3 (de) * 1967-10-12 1975-03-20 Shell Internationale Research Maatschappij B.V., Den Haag (Niederlande) Arzneimittel mit thymeretischer Wirkung
GB1223492A (en) * 1967-10-13 1971-02-24 American Home Prod Guanidines
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
US4311701A (en) * 1979-08-16 1982-01-19 Barbara Roth Treatment of convulsions with triazines

Also Published As

Publication number Publication date
AU5890680A (en) 1980-12-04
US4602017A (en) 1986-07-22
UA5576A1 (uk) 1994-12-28
DK233880A (da) 1980-12-02
GR68380B (enExample) 1981-12-28
CZ384891A3 (en) 1993-10-13
DK153787C (da) 1989-01-16
JPS6133163A (ja) 1986-02-17
MY8500062A (en) 1985-12-31
AU566870B2 (en) 1987-11-05
EP0021121B1 (en) 1983-05-11
IT1147087B (it) 1986-11-19
FI67844B (fi) 1985-02-28
PL224633A1 (enExample) 1981-02-13
IE801126L (en) 1980-12-01
CA1112643A (en) 1981-11-17
ATA289680A (de) 1982-07-15
IL60201A0 (en) 1980-07-31
EP0059987B1 (en) 1985-08-14
AR227521A1 (es) 1982-11-15
FI67844C (fi) 1985-06-10
IT8048848A0 (it) 1980-05-30
US4486354A (en) 1984-12-04
YU145680A (en) 1983-02-28
ES8104993A1 (es) 1981-05-16
ZA803250B (en) 1982-01-27
HU182086B (en) 1983-12-28
DD151309A5 (de) 1981-10-14
JPH0144179B2 (enExample) 1989-09-26
IE49823B1 (en) 1985-12-25
MX9202962A (es) 1992-07-01
NL950007I1 (nl) 1995-06-16
IL60201A (en) 1984-05-31
NL950007I2 (nl) 1997-02-03
FI801758A7 (fi) 1980-12-02
PL124029B1 (en) 1982-12-31
NZ193890A (en) 1984-07-06
ES491998A0 (es) 1981-05-16
EP0021121A1 (en) 1981-01-07
SU1055331A3 (ru) 1983-11-15
JPH0144706B2 (enExample) 1989-09-29
EP0059987A1 (en) 1982-09-15
JPS5625169A (en) 1981-03-10
GEP19960470B (en) 1996-08-29
DK153787B (da) 1988-09-05
BG60427B2 (bg) 1995-03-31
CS234018B2 (en) 1985-03-14
ZW12980A1 (en) 1982-01-06
AT370097B (de) 1983-02-25

Similar Documents

Publication Publication Date Title
AU5890680A (en) Substituted amino triazines and their use in treatment of cns disorders
ZA804180B (en) Medicaments for the treatment of disorders in lipometabolism and their use
DE3363472D1 (en) Process for the preparation of n-substituted n-cyano-amides and their use
PT79555B (en) Highly purified protein production and use thereof
ZM6780A1 (en) Preparations for the treatment of theileriosis and their use
IL64047A0 (en) Spiro-quaternary ammonium halides and their use in the preparation of n-(2-pyrimidinyl)piperazinyl-alkylazaspiroalkanediones
EP0069232A3 (en) Purified antineoplaston fractions and methods of treating neoplastic disease
GB2114616B (en) Hair treatment process and composition
DE3164345D1 (en) Novel triamine derivatives and their use
DE3069260D1 (en) N-azidosulfonylaryl maleimides and their use
GB2211192B (en) Composition and process for the treatment and care of the hair
GB8908831D0 (en) Treatment of inflammatory disorders in humans
AU530790B2 (en) Triazinones and their use in treating gastrointestinal disorders
GR880300190T1 (en) Composition and process for permanently waving the hair
JPS57184659A (en) Grinding article and its manufacture
GB2071091B (en) Acyl-derivatives of carnitine and the therapeutic use thereof
GB2203645B (en) Improvements in the treatment of hair
DE3171366D1 (en) The dressing and forming of grinding wheels
GB2103216B (en) Process for the preparation of n-substituted methacrylamides and acrylamides
DE3362345D1 (en) Mixtures of specific 1,2-cycloaliphatic diepoxydes, and use thereof
JPS5595926A (en) Treating contact lens and treatment composition
PH17355A (en) Ergots and their use in treating minimal brain dysfunction
GB2049691B (en) Process for the preparation of 6-(substituted amino)-3-pyridazinylhydrazines and their salts
GB2086903B (en) Novel quinazolinones and their use in the preparation of triazoloquinazolinone derivatives
GB2040681B (en) Use in the treatment of hypertension and intestinal disorders of certain n - aryl - n - (2-imidazolidinylidene)-urea